Another five targetable gene dependencies had clinical inhibitors that have reached at least a phase II trial (BIRC2, ITGB1, MAP3K11, LDHA and PTPN1), with 3 having been applied to other cancer types (BIRC2, ITGB1, and LDHA). Here, BIRC2 is linked to cancer.